In line with this study, EV markers from NSCLC tumors and serum showed significantly lower levels of exosomal markers (CD63, CD81, EGFR, and PD-L1) after treatment with the TLM_CFM-F_OSM combination in the present study. This evidence concerns the gene CD81 and non-small cell lung carcinoma.